Compare Amylx Pharmaceuticals Inc (AMLX) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.3 (market cap $1.98B), while Sibanye Stillwater Ltd trades at $8.31 (market cap $5.95B). The key difference: Sibanye Stillwater Ltd is far larger — about 3× Amylx Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 3.64% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SBSW | |
|---|---|---|
Market Cap | $1.98B | $5.95B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $21.12 |
52-Week Low | $7.64 | $7.27 |
Enterprise Value | $1.70B | $7.57B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Sibanye Stillwater (SBSW) trades at $8.55, down 0.12% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.30 billion in 2024, though revenue stabilized at $112.13 billion. Recent news highlights a potential turnaround with EBITDA growth and debt reduction plans, while analyst consensus is mixed with 42.9% buy ratings.
The outlook hinges on operational improvements and commodity price recovery. Key risks include persistent negative margins and high debt levels, but low valuation multiples may attract value investors if the company executes its turnaround strategy effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
